Publications

5674 Results

Phase III Trial (Prevention of Early Menopause Study [POEMS]-SWOG S0230) of LHRH Analog during Chemotherapy to Reduce Ovarian Failure in Early Stage, Hormone-Receptor Negative Breast Cancer: An International Intergroup Trial of SWOG, IBCSG, ECOG, CALGB (Alliance)

Authors
HCF Moore;JM Unger;K-A Phillips;F Boyle;E Hitre;D Porter;P Francis;L Minasian;R Gelber;LJ Goldstein;HL Gomez Moreno;C Vallejos;AH Partridge;S Dakhil;S Martino;W Barlow;C Fabian;FL Meyskens;GN Hortobagyi;K Albain
Journal / Conference
Journal of Clinical Oncology 32:5s (suppl; abstr LBA505); ASCO Annual Meeting (May 30-June 3, 2014, Chicago, IL), oral;
Year
2014
Research Committee(s)
Breast
Study Number(s)
S0230

SWOG S0307 phase III trial of bisphosphonates as adjuvant therapy in primary breast cancer: Comparison of toxicities and patient-stated preference for oral versus intravenous delivery (ClinicalTrials.gov Identifier: NCT00127205)

Authors
JR Gralow;WE Barlow;A Paterson;D Lew;A Stopeck;DF Hayes;DL Hershman;M Schubert;M Clemons;CH Van Poznak;BE Dees;JN Ingle;C Falkson;AD Elias;M Messino;JH Margolis;S Dakhil;H Chew;R Livingston;G Hortobagyi
Journal / Conference
Journal of Clinical Oncology 32:5s (suppl; abstr 558); ASCO Annual Meeting (May 30-June 3, 2014, Chicago, IL), general poster session;
Year
2014
Research Committee(s)
Breast
Study Number(s)
S0307

SWOG S0809: A phase II trial of adjuvant capecitabine (cap)/gemcitabine (gem) followed by concurrent capecitabine and radiotherapy in extrahepatic cholangiocarcinoma (EHCC) and gallbladder carcinoma (GBCA)

Authors
E Ben-Josef;K Guthrie;AB El-Khoueiry;CL Corless;MM Zalupski;A Lowy;CR Thomas;SR Alberts;LE Dawson;KC Micetich;MB Thomas;A Siegel;CD Blanke
Journal / Conference
Journal of Clinical Oncology 32:5s (suppl; abstr 4030);ASCO Annual Meeting (May 30-June 3, 2014, Chicago, IL), poster highlights session;
Year
2014
Research Committee(s)
Gastrointestinal
Study Number(s)
S0809

SWOG S0925: A randomized phase 2 study of androgen deprivation combined with cixutumumab (IMC-A12) versus androgen deprivation alone for patients with new metastatic castration-sensitive prostate cancer

Authors
EY Yu;CM Tangen;C Higano;N Agarwal;SK Pal;A Alva;E Heath;ET Lam;S Gupta;M Lilly;Y Inoue;KN Chi;NJ Vogelzang;DI Quinn;H Li;H Cheng;H Plymate;MHA Hussain;IM Thompson
Journal / Conference
Journal of Clinical Oncology 32:5s (suppl; abstr 5006); ASCO Annual Meeting (May 30-June 3, 2014, Chicago, IL), oral session;
Year
2014
Research Committee(s)
Genitourinary
Study Number(s)
S0925

Comparison of plasma microRNAs with CTCs and PSA in patients treated on SWOG S0925, a randomized phase II study of androgen deprivation combined with cixutumumab versus androgen deprivation alone for patients with new metastatic hormone-sensitive prostate cancer

Authors
HH Cheng;H Li;C Higano;C Tangen;N Agarwal;J Yan;N Vogelzang;MHA Hussain;IM Thompson;M Tewari;EY Yu
Journal / Conference
Journal of Clinical Oncology 32:5s (suppl; abstr 5017); ASCO Annual Meeting (May 30-June 3, 2014, Chicago, IL), poster highlights session;
Year
2014
Research Committee(s)
Genitourinary
Study Number(s)
S0925

Omega-3-fatty acids for aromatase inhibitor-induced musculoskeletal symptoms in women with early stage breast cancer (SWOG S0927)

Authors
D Hershman;J Unger;K Crew;S Dakhil;D Awad;H Greenlee;L Minasian;L Hansen;K Kaberle;D Lew;J Gralow;J Wade;F Meyskens;C Moinpour
Journal / Conference
Journal of Clinical Oncology 32:5s (suppl; abstr 9532); ASCO Annual Meeting (May 30-June 3, 2014, Chicago, IL), poster highlights session;
Year
2014
Research Committee(s)
Symptom Management and Survivorship
Study Number(s)
S0927

A Phase II Study of MK-2206, an Allosteric Inhibitor of AKT as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction (GEJ) Cancer, a SWOG Cooperative Group Trial (S1005)

Authors
R Ramanathan;S McDonough;H Kennecke;S Iqbal;J Baranda;T Seery;H Lim;AF Hezel;G Vaccaro;CD Blanke
Journal / Conference
Journal of Clinical Oncology 32:5s (suppl; abstr 4041); ASCO Annual Meeting (May 30-June 3, 2014, Chicago, IL), general poster session;
Year
2014
Research Committee(s)
Gastrointestinal
Study Number(s)
S1005

US Intergroup Phase II Trial (SWOG S1108) of Alisertib, an Investigational Aurora A Kinase (AAK) Inhibitor, in Patients with Peripheral T-Cell Lymphoma (PTCL) (NCT01466881)

Authors
P Barr;H Li;C Spier;D Mahadevan;J Friedberg;M Leblanc;M Ul Haq;C Flowers;N Wagner-Johnston;SM Horwitz;B Cheson;TP Miller;RI Fisher
Journal / Conference
Journal of Clinical Oncology 32:5s (suppl; abstr 8523); ASCO Annual Meeting (May 30-June 3, 2014, Chicago, IL), poster highlights session;
Year
2014
Research Committee(s)
Lymphoma
Study Number(s)
S1108

A Randomized Placebo-Controlled Phase III Study of Duloxetine for Treatment of AromataseInhibitor (AI)-Associated Musculoskeletal Symptoms in Women with Early Stage Breast Cancer: SWOG S1202

Authors
NL Henry;J Unger;A Schott;L Hansen;D Lew;J Wade;C Moinpour;GN Hortobagyi;FL Meyskens
Journal / Conference
Journal of Clinical Oncology 32:5s (suppl; abstr TPS9662); ASCO Annual Meeting (May 30-June 3, 2014, Chicago, IL), general poster session;
Year
2014
Research Committee(s)
Symptom Management and Survivorship
Study Number(s)
S1202

SWOG 1211: a randomized phase I/II study of optimal induction therapy of bortezomib, dexamethasone and lenalidomide with or without elotuzumab for newly diagnosed high risk multiple myeloma (HRMM)

Authors
SZ Usmani;A Hoering;R Sexton;S Ailwahdi;JJ Shah;S Fredette;B Durie;J Zonder;M Dhodapkar;SV Rajkumar;T Zimmerman;P Richardson;RZ Orlowski
Journal / Conference
Journal of Clinical Oncology 32:5s (suppl; abstr TPS8624); ASCO Annual Meeting (May 30-June 3, 2014, Chicago, IL), general poster session;
Year
2014
Research Committee(s)
Myeloma
Study Number(s)
S1211